Fig. 1From: Immunogenicity of pembrolizumab in patients with advanced tumorsPembrolizumab ADA patient analysis. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent; TE, treatment-emergentBack to article page